Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Reported by Yahoo Finance · Published 24 Aug 2026, 6:20 AM MYT (1 hr ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery? 1 hr ago The next big oil trade may have nothing to do with oil stocks 1 hr ago Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable? 1 hr ago The $70M business behind Ballerina Farm 1 hr ago Fast fashion giant Shein launches up to $1.8 billion Hong Kong IPO 1 hr ago Stock futures slip as U.S. and Canada appear headed for trade war 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Summary

More in Markets

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?

The next big oil trade may have nothing to do with oil stocks

Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

The $70M business behind Ballerina Farm

Stock futures slip as U.S. and Canada appear headed for trade war

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?